156. Rett syndrome Clinical trials / Disease details
Clinical trials : 40 / Drugs : 53 - (DrugBank : 19) / Drug target genes : 77 - Drug target pathways : 113
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02715115 (ClinicalTrials.gov) | March 2016 | 21/2/2016 | A Safety Study of NNZ-2566 in Pediatric Rett Syndrome | A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett Syndrome | Rett Syndrome | Drug: NNZ-2566;Drug: Placebo | Neuren Pharmaceuticals Limited | rettsyndrome.org | Completed | 5 Years | 15 Years | Female | 82 | Phase 2 | United States |
2 | NCT01703533 (ClinicalTrials.gov) | March 2013 | 4/10/2012 | A Safety Study of NNZ-2566 in Patients With Rett Syndrome | A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome | Rett Syndrome | Drug: NNZ-2566;Drug: Placebo | Neuren Pharmaceuticals Limited | Baylor College of Medicine;International Rett Syndrome Foundation | Completed | 16 Years | 45 Years | Female | 67 | Phase 2 | United States |